The FDA fully approved Humacyte’s HUMA Symvess, a bioengineered vascular conduit, for treating extremity arterial injuries. Symvess provides a faster, off-the-shelf alternative to traditional vein grafts, reducing surgery time and patient trauma. The approval is supported by clinical trial data and real-world evidence from Ukraine. This breakthrough offers a significant advancement in treating life-threatening vascular injuries.